iRhythm projects revenue for the full year 2023 to grow approximately 18% to 19% compared to prior year results, ranging from approximately $485 million to $490 million. Gross margin for the full year 2023 is expected to range from 69% to 70% and adjusted operating expenses are expected to range between $417 million and $427 million. Adjusted EBITDA margin for the full year 2023 is expected to range from approximately 0% to 0.5% of revenues.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IRTC:
- Zio Granted High Medical Needs Designation by the Japanese Ministry of Health, Labour, and Welfare
- iRhythm Technologies to Report Second Quarter 2023 Financial Results on August 3, 2023
- iRhythm initiated with an Outperform at Baird
- NAMCP Independent Third-Party Review Validates Value Proposition of iRhythm Zio XT Service to Health Systems and Payers
- iRhythm announces third-party review conducted by NAMCP validated Zio XT